Overview Dose-finding, Safety, Efficacy Trial of Topical Resiquimod in Patients With Multiple Actinic Keratosis Lesions Status: Completed Trial end date: 2014-06-01 Target enrollment: Participant gender: Summary A Dose-Finding Study of Resiquimod Evaluating Safety and Efficacy in Patients with Multiple Actinic Keratosis Lesions Phase: Phase 2 Details Lead Sponsor: Spirig Pharma Ltd.